What tests are included in the universal newborn screening panel for newborn infants?

Universal Newborn Screening Tests

Universal newborn screening should include a core panel of 29 conditions that meet strict criteria for early detection and treatment benefit, with the most critical being phenylketonuria (PKU), congenital hypothyroidism (CH), and medium-chain acyl-CoA dehydrogenase deficiency (MCAD). 1

Core Screening Panel Categories

The uniform screening panel encompasses three main disease categories, all tested from a single dried blood spot collected 24-48 hours after birth 1:

Metabolic Disorders (23 conditions detected primarily by tandem mass spectrometry)

• Nine organic acidurias including glutaryl-CoA dehydrogenase deficiency 1, 2
• Six amino acid disorders including phenylketonuria (PKU) 1, 3
• Five fatty acid oxidation disorders including medium-chain acyl-CoA dehydrogenase deficiency (MCAD) 1, 2

Hemoglobinopathies

• Three conditions associated with hemoglobin S allele (sickle cell disease and variants) 1, 3

Other Critical Conditions

• Congenital hypothyroidism - universally mandated in all 51 U.S. jurisdictions 3
• Cystic fibrosis 2
• Congenital adrenal hyperplasia 2
• Severe combined immunodeficiency (SCID) - added to recommended panel in 2010, now implemented in all 50 states 4
• Critical congenital heart disease (CCHD) - added in 2011, implemented nationwide 4
• Congenital hearing loss 5

Recently Added Conditions

More recent additions to the Recommended Uniform Screening Panel (RUSP) include 4:

• Pompe disease (glycogen storage disease type II) - added 2015, now in 37 state programs
• Mucopolysaccharidosis type I (MPS I) - added 2016, now in 34 programs
• X-linked adrenoleukodystrophy (X-ALD) - added 2016, now in 32 programs
• Spinal muscular atrophy (SMA) - added 2018, most rapidly adopted with 48 programs screening as of 2022

Inclusion Criteria

For a condition to qualify as a primary screening target, it must meet three mandatory criteria 1:

1. Detectable in the presymptomatic phase at 24-48 hours after birth when clinical signs are absent
2. Validated screening test available with appropriate sensitivity and specificity
3. Proven benefit from early intervention with available efficacious treatment that improves outcomes

Secondary Targets

Beyond the 29 core conditions, an additional 25 secondary target conditions are identified as part of differential diagnosis during screening or follow-up testing 1. These are clinically significant findings that may be revealed by the multiplex technologies (particularly tandem mass spectrometry) used to detect primary targets.

Important Caveats

State-level variation exists - While the Advisory Committee on Heritable Disorders in Newborns and Children recommends 34 core conditions, each state independently manages and funds its own program, leading to significant variation in which conditions are actually screened 5. The pace of adoption for newly recommended conditions varies considerably, with implementation taking 5-11 years on average 4.

Screening is not diagnostic - All positive screening results require confirmatory diagnostic testing 6. The screening system must include coordinated follow-up, diagnosis, treatment, and long-term management, not just the initial test 1.

Technology drives expansion - The widespread adoption of tandem mass spectrometry has enabled simultaneous screening for multiple metabolic disorders from a single blood spot, fundamentally expanding screening capabilities 1, 2.